Company Overview and News
XTEK Ltd (ASX:XTE) managing director Philippe Odouard tells Proactive Investors that the '21st Century' homeland security specialist company is building upon its profitable traditional business with two new product lines.
XTEK Ltd (ASX:XTE) has achieved an (unaudited) revenue of about $17.3 million for the year ending 30 June 2018, which is at the upper end of its guidance range and represents a significant increase from FY2017 revenue ($9 million).
XTEK Ltd (ASX:XTE) achieved revenue of $17.2 million in FY18, up 91% on the prior year and notably in the upper end of the previously guided range of $11 to $18 million.
XTEK Ltd (ASX:XTE) has received the first domestic purchase order from the Australian Defence Force (ADF) for its proprietary small arms protective insert (SAPI) plates.
The developer and manufacturer of protection, military and surveillance products continues to win new contracts in realising mid-range revenue guidance of about $14 million.
XTEK Ltd (ASX:XTE) has achieved year to date revenue of $8.3 million and maintains its FY2018 guidance of between $11 million and $18 million.
XTEK Ltd (ASX:XTE) has received a purchase order from the Australian Defence Force (ADF) worth A$1.4 million.
XTEK Ltd (ASX:XTE) director Uwe Boettcher has demonstrated his confidence in the company’s strategy by increasing his shareholding.
XTEK Ltd (ASX:XTE) is well positioned for rapid near-term revenue growth in 2018 after finishing the 2017 calendar year with record orders in hand of $42 million, the highest in the history of the company.
BAESY LMT NOC XTE QCKSF BA BAESF QHL
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...